• 1
    Surveillance, Epidemiology, and End Result Program: SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute. Available at:http://seer.cancer. gov/csr/1976_2006/ Accessed March 8, 2010.
  • 2
    Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer. 2006; 107: 982-990.
  • 3
    Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 in transitional cell carcinoma: why? Eur Urol. 2004; 45: 539-546; discussion 546.
  • 4
    Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol Suppl. 2008;( 218): 213-233.
  • 5
    Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol. 1999; 13: 117-121.
  • 6
    Jichlinski P, Forrer M, Mizeret J, et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med. 1997; 20: 402-408.
  • 7
    Kriegmair M, Baumgartner R, Knuechel R, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994; 44: 836-841.
  • 8
    Kriegmair M, Stepp H, Steinbach P, et al. Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Urol Int. 1995; 55: 190-196.
  • 9
    Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002; 168: 475-478.
  • 10
    Schellhammer PF. Immediate adjuvant intravesical chemotherapy after transurethral resection of bladder tumor. Curr Opin Urol. 1998; 8: 407-409.
  • 11
    Stenzl A, Jocham D, Jichlinski P, et al. Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A. 2008; 47: 982-987.
  • 12
    Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005; 96: 798-802.
  • 13
    Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002; 168: 67-71.
  • 14
    Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995; 153(3 pt 2): 934-941.
  • 15
    Hall M, Chang S, Dalbagni G, et al. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178: 2314-2330.
  • 16
    Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol. 2002; 41: 105-112.
  • 17
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22: 1435-1448.
  • 18
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. 5thed. New York, NY: Wiley-Liss; 1997.
  • 19
    Collett D. Modelling Survival Data in Medical Research. 2nd ed. London, UK: Chapman & Hall/CRC; 1994.
  • 20
    Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174: 2129-2133; discussion 2133.
  • 21
    Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007; 69: 675-679.
  • 22
    Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004; 171: 135-138.
  • 23
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008; 54: 303-314.
  • 24
    Bachor R, Reich E, Ruck A, Hautmann R. Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. Urol Res. 1996; 24: 285-289.
  • 25
    Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer—a multicenter study. J Urol. 2003; 170: 226-229.
  • 26
    Lopez RF, Bentley MV, Delgado-Charro MB, et al. Enhanced delivery of 5-aminolevulinic acid esters by iontophoresis in vitro. Photochem Photobiol. 2003; 77: 304-308.
  • 27
    Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55: 815-825.